PCI expands cold chain storage capabilities at UK site
The announcement is the latest in a series of strategic investments at PCI, demonstrating its market-leading presence in Biotech therapies, supporting medicines destined reach to more than 100
The National Medical Products Administration (NMPA) of China has approved Keymed Biosciences’ new drug application granting marketing approval for Stapokibart to treat adults with moderate-to-severe atopic dermatitis.
In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor,